We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Getein Biotech Presents Sustainable Lab Solutions with Unlimited Possibilities at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022
Print article
Image: Getein’s POCT testing solutions meet the different needs of laboratory detection (Photo courtesy of Getein Biotech)
Image: Getein’s POCT testing solutions meet the different needs of laboratory detection (Photo courtesy of Getein Biotech)

Getein Biotech, Inc. (Nanjing, China) is presenting its sustainable diagnostic solutions that offer unlimited possibilities for laboratories at the 2022 AACC Clinical Lab Expo.

AT AACC 2022, Getein will exhibit its range of POCT immunofluorescence quantitative analyzers, including the Getein1160, Getein1180, Getein1200 and Getein1600. These immunofluorescence quantitative analyzers automate the detection and quantification of markers for cardiovascular diseases, renal diseases, inflammation, fertility, diabetes mellitus, bone metabolism, tumor, and thyroid in biological samples. Getein is also showcasing the MAGICL6000 chemiluminescence immunoassay analyzer that automates the detection and quantification of markers for thyroid disease, inflammation, cardiac diseases, fertility, diabetes mellitus, bone metabolism, tumor, infectious disease, anemia, and immune globulin by analyzing human serum, plasma, whole blood and urine samples.

In addition, Getein will exhibit the fully automated CM-400 clinical chemistry analyzer for the quantitative analysis of chemical components in human serum, plasma, whole blood, urine, and cerebrospinal liquid samples. CM-400 is characterized by open reagents, discrete system, emergency priority, random access and an external computer. The analyzer consists of the main instrument and the computer with the main instrument composed of an optical system, reaction system, sample adding system, reagent adding system, cleaning system and mixing system, with an optional electrolyte module.

Getein is also highlighting the BHA-3000 and BHA-5000 automatic hematology analyzers that provide quantitative analysis of a patient's blood components at high speed with accuracy, alongside the XN06 semi-automated blood coagulation analyzer for testing four routine clotting test items, namely PT, TT, APTT and FIB. Getein will demonstrate its One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) for the qualitative detection of SARS-CoV-2 antigens in human nasal swab samples. The test is suitable for medical laypersons as a self-test at home or at work. Getein provides a comprehensive range of COVID-19 testing solutions, including neutralizing antibody tests, antigen tests and IgM/IgG antibody tests. Getein also offers the Monkeypox Virus Real-time PCR Kit for the qualitative detection of MPV in serum or lesion exudate samples.
 

Related Links:
Getein Biotech, Inc. 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.